Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AARD stock hub

Aardvark Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AARDis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

118.7M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

AARD

In the news

Latest news · AARD

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-58.8

P25 -105.6P50 -46.5P75 -3.1

ROIC-39.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AARD market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

172

Groups with data

Currency

USD

Showing 172 of 172 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001774857
Company name	Aardvark Therapeutics, Inc.
Country	United States
Country code	US
Cusip	002942100
Employees	40
Employees Change	18%
Employees Change Percent	81.82
Enterprise value	$27.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2025-02-13
Isin	US0029421007
Last refreshed	2026-05-10
Market cap	$118.7M
Market cap category	Micro-Cap
Price	$5.44
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	AARD
Website	https://aardvarktherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-58.87%
FCF yield	-52.03%
P/B ratio	1.36x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-69.9M
Net Income Growth Years	0%
Profit Per Employee	$-1.7M
ROA	-36.54
ROCE	-85.9
ROE	-58.79
ROIC	-39.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-48.85%
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$98.6M
Cash	$91.2M
Current Assets	$93.6M
Current Liabilities	$11.6M
Debt	$336,000
Debt Equity	$0
Equity	$87M
Liabilities	$11.6M
Long Term Assets	$5M
Long Term Liabilities	$0
Net Cash	$90.9M
Net Cash By Market Cap	$76.56
Net Cash Growth	-39.64%
Net Debt Equity	$-1.04
Tangible Book Value	$87M
Tangible Book Value Per Share	$3.99

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.06
Net Working Capital	$-8.9M
Quick ratio	7.86
Working Capital	$82M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-245.54%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-48.82%
200-day SMA	10.41
50-day SMA	5.05
50-day SMA vs 200-day SMA	50under200
All Time High	19.58
All Time High Change	-72.22%
All Time High Date	2025-02-20
All Time Low	3.35
All Time Low Change	62.39%
All Time Low Date	2026-03-27
ATR	0.43
Beta1y	3.42
Beta2y	2.31
Ch YTD	-58.55
High	5.65
High52	17.94
High52 Date	2025-10-08
High52ch	-69.68%
Low	5.3
Low52	3.35
Low52 Date	2026-03-27
Low52ch	62.39%
Ma50ch	7.77%
Premarket Change Percent	0
Premarket Price	$5.6
Price vs 200-day SMA	-47.76%
RSI	51.18
RSI Monthly	43.46
RSI Weekly	36.05
Sharpe ratio	-0.04x
Sortino ratio	-0
Total Return	-245.54%
Tr YTD	-58.55
Tr1m	34.65%
Tr1w	-0.37%
Tr3m	-57%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	9
Analyst Count Top	2
Analyst Price Target Top	$14
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.89
Operating Income	$-74.7M
Price target	$15.29
Price Target Change	$181
Price Target Change Top	$157

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10,863,468%
Float Percent	49.8%
Shares Insiders	16.33%
Shares Institutions	25.41%
Shares Out	21,816,385
Shares Qo Q	0.15%
Shares Yo Y	245.54%
Short Float	10.62%
Short Ratio	4.51
Short Shares	5.29

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-67.5M
Average Volume	144,894.4x
Bv Per Share	3.99
CAPEX	$-95,000
Ch1m	34.65
Ch1w	-0.37
Ch1y	-48.82
Ch3m	-57
Ch6m	-46.35
Change	-2.86%
Change From Open	-3.55
Close	5.6
Days Gap	0.71
Depreciation Amortization	42,000
Dollar Volume	456,970.9
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-74.7M
EBITDA	$-74.7M
EPS	$-3.21
F Score	1
FCF	$-61.7M
FCF EV Yield	-221.98x
FCF Per Share	$-2.83
Financing CF	378,000
Fiscal Year End	December
Founded	2,017
Investing CF	97,207,000
Ipr	-66
Iprfo	-64.16
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-23
Ma150	10.24
Ma150ch	-46.85%
Ma20	5.31
Ma20ch	2.51%
Net CF	35,932,000
Next Earnings Date	2026-08-12
Open	5.64
Optionable	Yes
Position In Range	40
Post Close	5.44
Postmarket Change Percent	-3.49
Postmarket Price	$5.25
Ppne	269,000
Pre Close	5.6
Price Date	2026-05-08
Ptbv Ratio	1.36
Relative Volume	0.58x
Share Based Comp	5,719,000
Tr6m	-46.35%
Us State	California
Volume	84,002

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AARD pay a dividend?

Capital-return profile for this ticker.

Performance

AARD stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AARD?

Insider, institutional, and short-interest positioning.

Institutional ownership

+25.4%

Float: +49.8% of shares outstanding

Insider ownership

+16.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

AARD momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.2

Neutral momentum band

Price vs 200-day MA

-47.8%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.04

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AARD

Hub-level FAQ points readers to the deeper analysis pages.

What is the current AARD stock rating?

Aardvark Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full AARD analysis?

The full report lives at /stocks/AARD/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for AARD?

The latest report frames AARD around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the AARD page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.